Prevalite

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prevalite

Property Description
Active ingredient Cholestyramine resin
Form Powder for Oral Suspension
Pharmacological class Bile Acid Sequestrant, Anion-Exchange Resin
Common Use Reduction of elevated cholesterol
Origin Synthetic polymer

What Type of Medicine is Prevalite?

Prevalite is a specific prescription-only medicine containing the active ingredient Cholestyramine resin, which belongs to the pharmacological class of bile acid sequestrants. This compound is a synthetic polymer, specifically an anion-exchange resin, meaning its chemical structure allows it to bind certain negatively charged molecules. Prevalite is offered as a lightly flavored version of the resin, designed to improve the palatability of the required oral suspension. As a pharmaceutical preparation, it is classified as a single-ingredient product supplied as a powder for oral suspension, requiring the patient to mix it with a fluid before the oral administration. The definitive identity of the product is rooted in its chemical structure: a chloride salt of a basic quaternary ammonium functional group polymer.


How Does the Cholestyramine Resin Function for General Benefit?

The core function of Cholestyramine resin is non-systemic, working solely within the gastrointestinal tract through a process called sequestration. This large, non-absorbable polymeric substance chemically binds to bile acids in the intestine, forming stable complexes that cannot be reabsorbed into the body. By interrupting the enterohepatic circulation—the body's natural recycling pathway for bile acids—the drug forces their irreversible fecal excretion. Cholestyramine is categorized as an essential medicine, and its role in lipid modification is well-established. This forced removal creates a metabolic demand in the liver, which then converts existing cholesterol into new bile acids, leading to an overall reduction of low-density lipoprotein cholesterol (LDL-C) in the bloodstream. The general therapeutic purpose of Prevalite is thus tied directly to reducing elevated cholesterol levels and relieving specific discomfort associated with bile acid buildup, an action that promotes the clearance of LDL-C from the blood.

Regulatory References

  1. NIH MedlinePlus Drug Information for Cholestyramine Resin

What side effects are possible with Prevalite?

Prevalite (cholestyramine resin) is a non-systemic medicine, meaning its safety profile is primarily focused on the gastrointestinal tract, where its action occurs. Regulatory documents categorize adverse reactions by frequency and system involvement, providing a framework for understanding potential risks.

Official Adverse Reaction Scope

Adverse reactions are most frequently classified as Gastrointestinal Disorders. The most consistently documented and Very Common adverse reaction is constipation, which may be dose-related and can worsen existing conditions like hemorrhoids. Other Common gastrointestinal effects include abdominal discomfort or pain, flatulence, nausea, and vomiting.

Serious Reactions and Malabsorption Risk

Due to the medicine's bile-binding mechanism, official labels document the risk of malabsorption of fat-soluble vitamins (A, D, E, K), particularly with long-term use. This systemic safety concern can lead to Hypoprothrombinemia (low blood clotting protein) and potentially an increased bleeding tendency, classified under Blood and Lymphatic System Disorders. Rarely documented but serious adverse reactions include fecal impaction (associated with severe constipation) and pancreatitis.

Safety Constraints and Special Populations

Cholestyramine is contraindicated in individuals with a complete biliary obstruction due to its mechanism of action. Safety documentation specifies that constipation may be more pronounced in the pediatric population and older adults. Furthermore, the medicine can affect the absorption of other orally administered medications, a safety note requiring caution when co-administering other drugs.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile of Prevalite (cholestyramine resin) primarily based on its non-absorbable nature, as the drug works only within the digestive tract.

Overdose Manifestations and Risks

The chief potential harm following overdosage is the development of a physical obstruction within the intestine or stomach. Overdose may be clinically characterized by the onset of severe constipation and severe stomach pain. This potential for physical blockage is classified as a severe outcome, with regulatory reports citing instances of life-threatening intestinal obstruction. Specific population considerations note that rare post-marketing reports of obstruction, including fatalities, have occurred in pediatric patients.

Emergency Action and Management

Immediate medical attention is required if severe gastrointestinal symptoms, such as severe stomach pain accompanied by nausea and vomiting, occur. Suspected overdosage should be reported to a regional poison control center. Management is strictly supportive, focusing on the clinical presentation of the obstruction. Because the resin is not absorbed systemically, no specific chemical antidote is known. Treatment is individualized and determined by the location and degree of the obstruction and the presence or absence of gut motility, as documented in the prescribing information.

Therapeutic Uses of Prevalite

What Prevalite Treats: Main Uses and Benefits

Prevalite (cholestyramine) is used to support the management of certain conditions. Its primary domain is as an adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with a condition known as primary hypercholesterolemia. This medication is administered to assist with the reduction of high concentrations of cholesterol in the blood.

A second therapeutic domain for Prevalite is to aid in the relief of itching (pruritus) when this symptom is associated with partial biliary obstruction. The use of this product is intended to help manage the discomfort caused by this specific symptom.

This medication offers a therapeutic effect that may address the causes of the specified symptoms. The reduction of cholesterol levels can be a component of a comprehensive, long-term health strategy.


Quick Fact: Relief for Itching (associated with partial biliary obstruction)

Eligibility and Restrictions for Use

Who Can and Cannot Use Prevalite?

The official eligibility profile for Prevalite (cholestyramine resin) is defined by specific regulatory criteria, establishing both absolute prohibitions and conditional use requirements.


Absolute Contraindications and Restrictions

Prevalite is strictly contraindicated in patients diagnosed with complete biliary obstruction, as the medicine's non-systemic binding action relies on the presence of bile in the intestine. It is also contraindicated for individuals with a known hypersensitivity to any component of the powder.

Additionally, therapy is initiated only after secondary causes of hypercholesterolemia (such as hypothyroidism or uncontrolled diabetes) have been excluded. Patients with pre-existing constipation require careful dose titration due to the risk of fecal impaction.


Population-Specific Eligibility Status

Population Group Regulatory Status
Complete Biliary Obstruction Contraindicated
Hypersensitivity Contraindicated
Adults Use Established for Labeled Indications
Pregnant Women Safety and Efficacy Not Established (Category C)
Pediatric Patients Long-term effects and safety are Unknown
Phenylketonurics (PKU) Must Avoid Sugar-Free Formulation (Contains Phenylalanine)

Use in pregnant women requires careful consideration as the safety and efficacy of the product in this group are not established by regulatory documents. Caution is also advised when administering the drug to nursing mothers and patients with renal insufficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Prevalite (cholestyramine resin) is a non-systemic drug, and its officially documented interactions are primarily based on physicochemical binding in the gastrointestinal tract, leading to reduced systemic exposure of co-administered oral medications.

Timing-Based Administration Requirements

To minimize the binding effect and avoid reduced absorption, a mandatory timing rule applies to nearly all other oral medicines. Regulatory information states that other oral drugs must be administered at least 1 hour before or 4 to 6 hours after the dose of Prevalite.

Documented Exposure-Altering Interactions

Reduced absorption due to binding is officially documented for several specific drugs and substance categories, requiring monitoring or dose adjustment in the regulatory labeling:

  • Coumarin Anticoagulants (e.g., Warfarin)
  • Cardiac Glycosides (e.g., Digoxin)
  • Thyroid Preparations (e.g., Levothyroxine)
  • Thiazide Diuretics
  • Estrogens and Progestins

Pharmacodynamic and Nutritional Interactions

Co-administration with other lipid-modifying agents, such as HMG-CoA Reductase Inhibitors (Statins) and Nicotinic Acid, has an officially described additive effect on cholesterol reduction. Furthermore, prolonged administration of Prevalite is documented to reduce the absorption of fat-soluble vitamins (A, D, E, K) and Folic Acid, which may lead to deficiency states.

Population-Specific Notes

The regulatory profile includes notes on an increased risk of hyperchloremic acidosis in pediatric patients and those with existing renal impairment due to the drug's formulation as a chloride salt. The drug is also restricted from use in patients with Complete Biliary Obstruction.

Mechanism of Action

The mechanism of action for Prevalite (cholestyramine) is based on its specialized function as a non-systemic bile acid sequestrant operating exclusively within the gastrointestinal tract.

Bile Acid Sequestration in the Intestinal Lumen

This process involves the drug acting as a non-absorbable polymer resin that physically binds to negatively charged bile acids in the small intestine. By forming this insoluble complex, the mechanism results in the increased fecal excretion of bile acids, preventing their return to the bloodstream.

Interruption of the Enterohepatic Circulation

The binding action directly interrupts the enterohepatic circulation, the natural pathway responsible for reabsorbing the majority of bile acids back to the liver. This pathway interference leads to a reduction in the bile acid pool, which acts as a key signal to the liver to initiate a compensatory metabolic response.

Hepatic Cholesterol Clearance Cascade

In response to the reduced bile acid return, the liver is signaled to increase bile acid synthesis to replenish the pool. This compensatory activity requires the liver to utilize its endogenous cholesterol stores for bile acid synthesis, which influences plasma levels of low-density lipoprotein (LDL) cholesterol.

Dosage and Administration Information

Prevalite is administered solely by the oral route as a powder for oral suspension, functioning non-systemically within the gastrointestinal tract. The powder must never be consumed in its dry form; instead, each dose must be thoroughly mixed with at least 2 to 6 ounces (60 to 180 mL) of liquid, such as water or a non-carbonated beverage, or a highly fluid food like applesauce, and stirred to a uniform consistency. The powder contains 4 grams of anhydrous cholestyramine resin, which serves as the standardized unit for all dosing calculations.

Administration involves taking the medicine in divided doses throughout the day, typically twice daily, often scheduled at mealtime. For adult use, the usual maintenance regimen falls within the range of 8 to 16 grams daily, though the maximum recommended daily intake is 24 grams. Initiation of treatment often begins at a lower amount, with subsequent dose increases being introduced gradually at intervals of not less than four weeks. A key procedural rule for this medication relates to the timing of other drugs: to prevent interference with their absorption, other oral medications must be taken either 1 hour before or 4 to 6 hours after the administration of the cholestyramine resin. Pediatric use for specific lipid conditions is governed by body weight, with a typical regimen of 240 mg/kg/day divided into two or three doses, which should not exceed 8 grams per day.

Recent Clinical Evidence

Research evidence / Overview of Studies for Prevalite


Evidence Supporting the Management of Elevated Cholesterol

Cholestyramine resin (the active ingredient in Prevalite) was evaluated in research focused on subjects with elevated cholesterol levels in long-term, large-scale Randomized Controlled Trials (RCTs). These studies tracked major clinical events, such as those related to cardiovascular outcomes and coronary mortality, alongside biomarker shifts in low-density lipoprotein cholesterol (LDL-C) and total cholesterol. Findings from these trials describe patterns where the incidence rate of major clinical events was observed to be different between the group receiving the study medicine and the group receiving the placebo. Research also examined patterns related to plaque buildup (atherosclerotic lesions).


Research for Relieving Itching (Pruritus)

The research on Cholestyramine resin explored patterns related to pruritus (itching) associated with partial bile duct obstruction through mechanism-based clinical investigations. Studies examined symptom intensity and monitored associated physiological factors, such as circulating bile acid levels. Clinical reports describe patterns where the severity of itching symptoms was observed to change in many patients during the study period. This area of research is considered to possess a Moderate level of evidence.


Long-Term Evidence and Durability of Response

Data on long-term follow-up for this medicine was derived from the core cholesterol-lowering trials, with participants being observed in studies for up to seven years or more. However, the long-term persistence of the observed measurements are not well characterized beyond the definitive clinical studies.


Key Evidence Gaps and Areas of Research Uncertainty

The key research for cholesterol was evaluated in a highly specific group: predominantly asymptomatic middle-aged men with elevated cholesterol levels. Because the results apply only to the populations studied, findings for women and older adults are not as comprehensive. Furthermore, data for the use in children remain insufficient, with limited information for long-term outcomes. For pruritus, the evidence quality varies across studies, and the follow-up durations were limited in many of the supporting research settings.

Key Studies & References

  1. Screening and Treatment for Hypercholesterolemia in Children and Adolescents: Systematic Evidence Review (USPSTF)

Frequently Asked Questions (FAQ)

Common questions about Prevalite (FAQ)

Q: Can Prevalite be used for conditions other than high cholesterol?

A: Yes, regulatory documents confirm that Prevalite (cholestyramine resin) is officially indicated for more than just lowering cholesterol. It is also used to relieve pruritus (itching) that is associated with partial biliary obstruction, a condition where the flow of bile is partially blocked.

Q: Is it normal to feel bloated when starting Prevalite?

A: Official product information lists flatulence (gas/bloating) and abdominal discomfort among the less frequently reported adverse reactions. Since Prevalite works entirely within the digestive tract, changes in bowel habits are commonly reported when starting treatment.

Q: Are there any long-term side effects associated with taking Prevalite?

A: Chronic use of the medicine may require patient monitoring, as regulatory information indicates that long-term use can lead to the reduced absorption of Vitamin K. This is associated with an increased bleeding tendency (hypoprothrombinemia). There is also a less common risk of hyperchloremic acidosis.

Q: Why do people mix Prevalite with apple sauce instead of water?

A: The official administration instructions require the powder to be thoroughly mixed with a liquid or highly fluid food, such as applesauce, before consumption. The mixing helps ensure the powder is fully suspended and reduces the risk of irritation and potential dental issues associated with the dry powder.

Q: Is Prevalite safe for use in children?

A: The official label indicates that experience with Prevalite in infants and children is limited, and long-term safety is not fully established. The potential for developing hyperchloremic acidosis (an excess of acid in the body) is a noted concern for younger patients, and careful monitoring is warranted as treatment is administered.

Q: Does taking Prevalite affect liver function tests?

A: Yes, the official adverse reactions section reports that liver function abnormalities have been among the events observed in patients taking cholestyramine resin.

Q: Is it better to take Prevalite with food or on an empty stomach?

A: Regulatory guidance suggests that it is generally recommended to take doses of the medicine with meals. The total daily dosage is typically administered in divided portions throughout the day, often scheduled around meal times.

Q: What should I do if I experience nausea after taking Prevalite?

A: Nausea is a reported side effect of the medicine. Official information suggests that maintaining adequate fluid and fiber intake can help manage general gastrointestinal discomfort. For persistent or severe nausea, patients should seek guidance from their healthcare provider.

Q: Can Prevalite raise triglyceride levels in some patients?

A: Yes, regulatory precautions state that a dose-related increase in serum triglycerides has been observed in clinical studies. Because of this risk, the regulatory label advises that serum triglyceride levels should be monitored periodically during treatment.

Q: Is it safe to drive or operate machinery while taking Prevalite?

A: Official safety documents list dizziness, vertigo, and drowsiness among the reported side effects. The presence of these potential side effects may temporarily affect a patient's capacity to drive or operate machinery.

Q: Does Prevalite have a shelf life or specific storage requirements?

A: The dry powder has an established shelf life, typically 3 years, and should be stored in its original container. It must be kept at temperatures that do not exceed 30 C (86 F).

Q: Can Prevalite affect blood sugar levels for someone who is not diabetic?

A: The regulatory label does not directly address blood sugar changes in non-diabetic patients. However, the official label notes that secondary causes of high cholesterol, such as uncontrolled diabetes, should be considered before initiating therapy.

Q: Does Prevalite contain any sugar or gluten?

A: The standard formulation of Prevalite contains sucrose (sugar) as an inactive ingredient. The sugar-free Light formulation contains aspartame and fructose. The presence or absence of gluten is not specifically noted in the regulatory ingredient listings.

Q: Why is hydration important when taking Prevalite powder?

A: The official product information strongly encourages patients to drink plenty of fluids during treatment. Adequate fluid intake helps manage the potential risk of severe constipation and a serious complication known as fecal impaction.

Q: Can being on Prevalite make certain foods taste different?

A: A sour taste is listed among the adverse events reported in patients taking cholestyramine resin. These events are reported in clinical settings.

Q: Are mood changes or anxiety reported side effects of Prevalite?

A: Anxiety is listed among the neurologic events reported in patients taking the medicine.

Q: Can Prevalite cause issues with dental health?

A: Official patient information states that holding the mixed suspension in the mouth for too long may lead to discoloration, erosion of enamel, or decay of the teeth. The potential for dental issues makes maintaining good oral hygiene an important consideration during therapy.

Q: Does Prevalite cause weight gain or weight loss?

A: Both weight loss and weight gain are listed among the events that have been reported in patients taking cholestyramine resin.

Q: Is there a link between Prevalite use and vitamin K deficiency?

A: Yes. The regulatory label states that chronic use of the medicine can interfere with the absorption of fat-soluble vitamins, potentially leading to hypoprothrombinemia (reduced blood clotting) associated with Vitamin K deficiency.

Q: Why is it important to mix the powder completely before drinking?

A: The medicine should be mixed with fluid to achieve a uniform consistency before consumption. Regulatory instructions stress that the powder should never be taken in its dry form.

Q: Is Prevalite a statin or a different type of cholesterol medication?

A: Prevalite belongs to a class of medicines called bile acid sequestrants, which is distinct from the statin class of drugs. Official information notes that Prevalite and statins may be used together, resulting in an additive effect for lowering cholesterol.

Q: How quickly does Prevalite start lowering cholesterol levels?

A: The effects are not immediate, as adjustments to the dose are typically made gradually. If a dosage increase is necessary, official guidelines recommend waiting not less than four weeks between adjustments to allow the body to respond to the medicine.

Q: What's the difference between Prevalite and generic cholestyramine?

A: Prevalite is a specific, brand-name formulation of the active ingredient cholestyramine resin. It is supplied as a lightly flavored version of the resin, intended to improve the taste and ease of taking the required oral suspension.

Q: Can Prevalite affect the absorption of vitamins or nutrients?

A: Yes, due to its mechanism of action, prolonged use is documented to reduce the body's absorption of fat-soluble vitamins (A, D, E, K) and Folic Acid. This can lead to deficiency states and is a key monitoring concern.

Q: Does Prevalite treatment require any routine blood monitoring?

A: Regulatory precautions strongly imply the need for monitoring. Because the medication can increase triglyceride levels and cause deficiencies in fat-soluble vitamins, levels of these substances should be checked periodically by a healthcare professional.

Q: Can Prevalite interact with herbal supplements like St. John's Wort?

A: Official interaction documents focus on prescription drugs like Warfarin, Digoxin, and thyroid preparations. While St. John's Wort is not specifically mentioned, the medicine’s binding action in the gut means there is a general potential for reduced absorption of many concurrently taken oral substances.

Q: How does Prevalite compare to other bile acid sequestrants?

A: Prevalite is a member of the pharmacological class known as bile acid sequestrants. Regulatory and product information establishes its action and efficacy within this class, but does not provide specific comparative data against other individual medicines in the same class.

Q: Does Prevalite help with LDL or HDL cholesterol more effectively?

A: Official documentation specifically describes the medicine's role in promoting the clearance and reduction of low-density lipoprotein cholesterol (LDL-C), often referred to as 'bad' cholesterol. Its effect on high-density lipoprotein cholesterol (HDL-C) is not documented in the same context.

How should Prevalite be stored and disposed of?

How to Store and Dispose of Prevalite?

Storage Requirements

The unmixed Prevalite powder must be stored at Controlled Room Temperature (CRT), maintaining a temperature range of 20 C to 25 C (68 F to 77 F). The product should be kept in a cool, dry place. The medicine must be stored out of the reach of children, as required by official labeling.

Stability and Handling

Once the powder is mixed with fluid to create the oral suspension, the prepared mixture is stable for up to three days when stored in the refrigerator. Short-term temperature fluctuations for the dry powder between 15 C and 30 C are permitted.

Disposal Instructions

Disposal of any unused or expired product must comply with federal, state, and local regulations. Official guidance recommends disposal by incineration and mandates that care should be taken to avoid environmental release of the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prevalite found in:

A-Z Index: